The Europe in vitro fertilization market size was exhibited at USD 9.15 billion in 2023 and is projected to hit around USD 15.05 billion by 2033, growing at a CAGR of 5.1% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 9.62 Billion |
| Market Size by 2033 | USD 15.05 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 5.1% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Procedure, Providers, Instruments, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | Germany; France; Spain; Italy; UK; Belgium; Netherlands; Switzerland |
| Key Companies Profiled | Vitrolife; Bayer AG; Ferring B.V.; Thermo Fisher Scientific Inc.; LG Chem; Merck KGaA |
One of the key factors driving the growth of this market is a rise in the prevalence of female and male infertility. According to Fertility Europe, 1 in 6 couples, or approximately 25 million people, have been suffering from infertility. This has increased the demand for in vitro fertilization (IVF) technology and treatments.
In 2023, the Europe in vitro fertilization market accounted fora 36.7% revenue share of the global in vitro fertilization market. The rise in infertility is among the major problems faced by the world population, and Europe is no exception to that. The lifestyle changes, increasing hours of work, sedentary nature of routines, consumption of chemicals and other harmful substances through food products that remain unnoticed, increasing prevalence of polycystic ovary syndrome, pelvic inflammatory disease, over/underactive thyroid glands, ovarian failure, conditions such as endometriosis, side effects caused by medicines and drugs, poor-quality semen in men, and hypogonadism are some of the major causes behind infertility. The growing occurrence of these aspects is expected to drive the growth of the market.
Technological advancements in IVF, supportive and encouraging government funding, the emergence of Physiological Intra-cytoplasmic Sperm Injection (PICSI), and strategic initiatives such as mergers & acquisitions (M&A) adopted by key companies have also been generating growth for this industry in Europe. In recent years, companies and governments have been concentrating on research and development associated with assistive technology to enhance the success rate of IVF. Some of the techniques introduced through the research include assisted hatching, egg/sperm freezing, vitrification, Percutaneous Epidydimal Sperm Aspiration & Testicular Sperm Extraction (PESA & TESE), three-parent IVF, genetic diagnosis, and mini-IVF.
The culture media segment dominated the market in 2023, with the largest revenue share. This can be attributed to aspects such as the availability of funding and an upsurge in research efforts to enhance the culture media. The culture media segment includes cryopreservation media, embryo culture media, ovary processing media, and sperm processing media.
The disposable devices segment is anticipated to witness the fastest CAGR over the forecast period. This segment is mainly driven by factors such as industry participants launching disposable devices, such as needles, chambers, and slides, to meet regulatory requirements. Such portfolio expansions are anticipated to increase the acceptance of disposable IVF devices.
The fertility clinics segment held the largest revenue share of 79.9% in 2023. A key factor attributing to this growth is the constantly growing demand for assisted reproductive technology (ART). In addition, the assistance provided by experts, cost-effectiveness, and less or no possibility of exposure to Hospital-Acquired Infections (HAIs) is generating growth for this segment.
The hospitals and other settings segment is expected to witness a CAGR of 4.6% from 2024 to 2033. Several specialty and multispecialty hospitals in the region offer helpful treatments for infertility, including In-vitro Fertilization (IVF). Increased availability and accessibility of such technology-assisted treatments have increased the inclination toward hospitals.
The frozen nondonor segment dominated the market with a revenue share of 48.13% in 2023. One of the main factors behind this larger share is cost-effectiveness. The less invasive nature of this procedure has also acted as an encouraging factor. The number of IVF cycles with the aid of frozen nondonor procedures is increasing compared to other procedures. This technique does not require fertility drug stimulation.
The fresh donor segment is anticipated to experience a significant CAGR of 5.3% from 2024 to 2033. The fresh donor eggs fertilize fresh oocytes. A greater number of people prefer this procedure as it tends to offer a greater success rate than the frozen eggs procedure.
Germany In Vitro Fertilization Market Trends
Germany in vitro fertilization market dominated the regional industry with a revenue share of 16.3% in 2023. This is primarily due to advancements in medical technologies and growing awareness regarding infertility and the availability of treatments for it. According to the National Library of Medicine, in Germany, 3% of children are conceived with the assistance of in vitro fertilization (IVF) technology.
Switzerland In Vitro Fertilization Market Trends
The in vitro fertilization market in Switzerland is expected to experience a CAGR of 6.0% from 2024 to 2033. According to the Federal Statistical Office, the number of children born in Switzerland through ART, specifically IVF, increased by 13% in 2021 compared to that of the previous year. The data indicates that approximately 2,500 children were born due to IVF treatments during that period.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe in vitro fertilization market
Instrument
Procedure
Providers
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.2. Market Definitions
1.2.1. Procedure Type
1.2.2. Providers
1.2.3. Instrument
1.2.4. Region
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.4.1. Information procurement
1.4.2. Purchased Database
1.4.3. Internal Database
1.4.4. Secondary Sources
1.4.5. Primary Research
1.4.6. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.6.1. Volume Price Analysis
1.6.2. Commodity Flow Analysis
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Research Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Procedure Type
2.2.2. End-Use
2.2.3. Instrument
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Segmentation
3.3. User Perspective Analysis
3.3.1. Consumer Behavior Analysis
3.3.2. Market Influencer Analysis
3.4. IVF Procedure Pricing Analysis
3.5. Market Dynamics
3.5.1. Market Driver Analysis
3.5.1.1. Rising reprotourism
3.5.1.2. Technological advancements in IVF
3.5.1.3. Favorable government funding
3.5.1.4. Late initiation of family
3.5.1.5. Increasing incidence rate of male and female infertility
3.5.1.6. Mergers and acquisitions (M&A)
3.5.2. Market Restraint Analysis
3.5.2.1. High cost of IVF treatment
3.5.2.2. Lack of regulatory framework and uniform regulations
3.5.2.3. Vulnerability of women depending on cross-border reprotourism
3.6. Industry Analysis Tools
3.6.1. Porter's Five Forces Analysis
3.6.2. PESTLE Analysis
3.6.3. Qualitative Analysis: Impact of COVID-19 on IVF Market
Chapter 4. In Vitro Fertilization Market: Procedure Type Analysis
4.1. In Vitro Fertilization by Procedure Type Market Share Analysis, 2023 & 2030
4.2. Segment Dashboard
4.3. Global In Vitro Fertilization Procedures Market, by Type, 2018 - 20302018 - 20302018 - 2030
4.4. Market Size and Forecasts and Trend Analysis, 2018 - 20302018 - 20302018 - 2030 for the Procedure Type
4.4.1. Fresh Nondonor
4.4.1.1. Fresh nondonor market, 2021 - 2033
4.4.2. Frozen Nondonor
4.4.2.1. Frozen nondonor market, 2021 - 2033
4.4.3. Fresh Donor
4.4.3.1. Fresh donor market, 2021 - 2033
4.4.4. Frozen Donor
4.4.4.1. Frozen donor market, 2021 - 2033
Chapter 5. In Vitro Fertilization Market: Providers Analysis
5.1. In Vitro Fertilization Market: Providers Market Share Analysis, 2023 & 2030
5.2. Segment Dashboard
5.3. Market Size and Forecasts and Trend Analysis, 2018 - 20302018 - 20302018 - 2030 for the following Providers
5.3.1. Fertility Clinics
5.3.1.1. Fertility clinics market, 2021 - 2033
5.3.2. Hospitals and Other Settings
5.3.2.1. Hospitals and other settings market, 2021 - 2033
Chapter 6. In Vitro Fertilization Market: Instrument Analysis
6.1. In Vitro Fertilization (IVF) Market Share Analysis, 2023 & 2030
6.2. Segment Dashboard
6.3. Global IVF Market, by Instrument, 2023 to 2030
6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Instrument
6.4.1. Culture Media
6.4.1.1. Culture media market, 2021 - 2033
6.4.1.2. Cryopreservation Media
6.4.1.2.1. Cryopreservation market, 2021 - 2033
6.4.1.3. Embryo Culture Media
6.4.1.3.1. Embryo culture media market, 2021 - 2033
6.4.1.4. Ovum Processing Media
6.4.1.4.1. Ovum processing media market, 2021 - 2033
6.4.1.5. Sperm Processing Media
6.4.1.5.1. Sperm processing media market, 2021 - 2033
6.4.2. Disposable Devices
6.4.2.1. Disposable devices market, 2021 - 2033
6.4.3. Equipment
6.4.3.1. Equipment market, 2021 - 2033
6.4.3.2. Sperm Analyzer Systems Media
6.4.3.2.1. Sperm analyzer systems market, 2021 - 2033
6.4.3.3. Imaging Systems
6.4.3.3.1. Imaging systems market, 2021 - 2033
6.4.3.4. Ovum Aspiration Pumps
6.4.3.4.1. Ovum aspiration pumps market, 2021 - 2033
6.4.3.5. Micromanipulator Systems
6.4.3.5.1. Micromanipulator systems market, 2021 - 2033
6.4.3.6. Incubators
6.4.3.6.1. Incubators market, 2021 - 2033
6.4.3.7. Gas Analyzers
6.4.3.7.1. Gas analyzers market, 2021 - 2033
6.4.3.8. Laser Systems
6.4.3.8.1. Laser systems market, 2021 - 2033
6.4.3.9. Cryosystems
6.4.3.9.1. Cryosystems market, 2021 - 2033
6.4.3.10. Sperm Separation Devices
6.4.3.10.1. Sperm separation devices market, 2021 - 2033
6.4.3.11. IVF Cabinets
6.4.3.11.1. IVF cabinets market, 2021 - 2033
6.4.3.12. Anti-vibration Tables
6.4.3.12.1. Anti-vibration tables market, 2021 - 2033
6.4.3.13. Witness Systems
6.4.3.13.1. Witness systems market, 2021 - 2033
6.4.3.14. Others
6.4.3.14.1. Others market, 2021 - 2033
Chapter 7. Regional Outlook
7.1. IVF Market by Region: Key Marketplace Takeaway
7.2. North America
7.2.1. North America IVF market, 2021 - 2033
7.2.2. U.S.
7.2.2.1. U.S. estimated fertility rate, 2021 - 2033
7.2.2.2. Regulatory framework
7.2.2.3. Reimbursement scenario
7.2.2.4. Competitive scenario
7.2.2.5. U.S. IVF market, 2021 - 2033
7.2.3. Canada
7.2.3.1. Canada estimated fertility rate, 2021 - 2033
7.2.3.2. Regulatory framework
7.2.3.3. Reimbursement scenario
7.2.3.4. Competitive scenario
7.2.3.5. Canada IVF market, 2021 - 2033
7.3. Europe
7.3.1. Europe IVF market, 2021 - 2033
7.3.2. France
7.3.2.1. France estimated fertility rate, 2021 - 2033
7.3.2.2. Regulatory framework
7.3.2.3. Reimbursement scenario
7.3.2.4. Competitive scenario
7.3.2.5. France IVF market, 2021 - 2033
7.3.3. Germany
7.3.3.1. Germany estimated fertility rate, 2021 - 2033
7.3.3.2. Regulatory framework
7.3.3.3. Reimbursement Scenario
7.3.3.4. Competitive scenario
7.3.3.5. Germany IVF market, 2021 - 2033
7.3.4. Italy
7.3.4.1. Italy estimated fertility rate, 2021 - 2033
7.3.4.2. Regulatory framework
7.3.4.3. Reimbursement scenario
7.3.4.4. Competitive scenario
7.3.4.5. Italy IVF market, 2021 - 2033
7.3.5. Spain
7.3.5.1. Spain estimated fertility rate, 2021 - 2033
7.3.5.2. Regulatory framework
7.3.5.3. Reimbursement scenario
7.3.5.4. Competitive scenario
7.3.5.5. Spain IVF market, 2021 - 2033
7.3.6. UK
7.3.6.1. UK estimated fertility rate, 2021 - 2033
7.3.6.2. Regulatory framework
7.3.6.3. Reimbursement scenario
7.3.6.4. Competitive scenario
7.3.6.5. UK IVF market, 2021 - 2033
7.3.7. Belgium
7.3.7.1. Belgium estimated fertility rate, 2021 - 2033
7.3.7.2. Regulatory framework
7.3.7.3. Reimbursement scenario
7.3.7.4. Competitive scenario
7.3.7.5. Belgium IVF market, 2021 - 2033
7.3.8. Netherlands
7.3.8.1. Netherlands estimated fertility rate, 2021 - 2033
7.3.8.2. Regulatory framework
7.3.8.3. Reimbursement scenario
7.3.8.4. Competitive scenario
7.3.8.5. Netherlands IVF market, 2021 - 2033
7.3.9. Switzerland
7.3.9.1. Switzerland estimated fertility rate, 2021 - 2033
7.3.9.2. Regulatory framework
7.3.9.3. Reimbursement scenario
7.3.9.4. Competitive scenario
7.3.9.5. Switzerland IVF market, 2021 - 2033
7.3.10. Sweden
7.3.10.1. Sweden estimated fertility rate, 2021 - 2033
7.3.10.2. Regulatory framework
7.3.10.3. Reimbursement scenario
7.3.10.4. Competitive scenario
7.3.10.5. Sweden IVF market, 2021 - 2033
7.3.11. Denmark
7.3.11.1. Denmark estimated fertility rate, 2021 - 2033
7.3.11.2. Regulatory framework
7.3.11.3. Reimbursement scenario
7.3.11.4. Competitive scenario
7.3.11.5. Denmark IVF market, 2021 - 2033
7.3.12. Norway
7.3.12.1. Norway estimated fertility rate, 2021 - 2033
7.3.12.2. Regulatory framework
7.3.12.3. Reimbursement scenario
7.3.12.4. Competitive scenario
7.3.12.5. Norway IVF market, 2021 - 2033
7.4. Asia Pacific
7.4.1. Asia Pacific IVF market, 2021 - 2033
7.4.2. Japan
7.4.2.1. Japan estimated fertility rate, 2021 - 2033
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement scenario
7.4.2.4. Competitive scenario
7.4.2.5. Japan IVF market, 2021 - 2033
7.4.3. China
7.4.3.1. China estimated fertility rate, 2021 - 2033
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement scenario
7.4.3.4. Competitive scenario
7.4.3.5. China IVF market, 2021 - 2033
7.4.4. India
7.4.4.1. India estimated fertility rate, 2021 - 2033
7.4.4.2. Regulatory framework
7.4.4.3. Reimbursement scenario
7.4.4.4. Competitive scenario
7.4.4.5. India IVF market, 2021 - 2033
7.4.5. Australia
7.4.5.1. Australia estimated fertility rate, 2021 - 2033
7.4.5.2. Regulatory framework
7.4.5.3. Reimbursement scenario
7.4.5.4. Competitive scenario
7.4.5.5. Australia IVF market, 2021 - 2033
7.4.6. South Korea
7.4.6.1. South Korea estimated fertility rate, 2021 - 2033
7.4.6.2. Regulatory framework
7.4.6.3. Reimbursement scenario
7.4.6.4. Competitive scenario
7.4.6.5. South Korea IVF market, 2021 - 2033
7.4.7. Thailand
7.4.7.1. Thailand estimated fertility rate, 2021 - 2033
7.4.7.2. Regulatory framework
7.4.7.3. Reimbursement scenario
7.4.7.4. Competitive scenario
7.4.7.5. Thailand IVF market, 2021 - 2033
7.5. Latin America
7.5.1. Latin America IVF market, 2021 - 2033
7.5.2. Brazil
7.5.2.1. Brazil estimated fertility rate, 2021 - 2033
7.5.2.2. Regulatory framework
7.5.2.3. Reimbursement scenario
7.5.2.4. Competitive scenario
7.5.2.5. Brazil IVF market, 2021 - 2033
7.5.3. Mexico
7.5.3.1. Mexico estimated fertility rate, 2021 - 2033
7.5.3.2. Regulatory framework
7.5.3.3. Reimbursement scenario
7.5.3.4. Competitive scenario
7.5.3.5. Mexico IVF market, 2021 - 2033
7.5.4. Argentina
7.5.4.1. Argentina estimated fertility rate, 2021 - 2033
7.5.4.2. Regulatory framework
7.5.4.3. Reimbursement scenario
7.5.4.4. Competitive scenario
7.5.4.5. Argentina IVF market, 2021 - 2033
7.6. Middle East & Africa
7.6.1. MEA IVF market, 2021 - 2033
7.6.2. South Africa
7.6.2.1. South Africa estimated fertility rate, 2021 - 2033
7.6.2.2. Regulatory framework
7.6.2.3. Reimbursement scenario
7.6.2.4. Competitive scenario
7.6.2.5. South Africa IVF market, 2021 - 2033
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia estimated fertility rate, 2021 - 2033
7.6.3.2. Regulatory framework
7.6.3.3. Reimbursement scenario
7.6.3.4. Competitive scenario
7.6.3.5. Saudi Arabia IVF market, 2021 - 2033
7.6.4. UAE
7.6.4.1. UAE estimated fertility rate, 2021 - 2033
7.6.4.2. Regulatory framework
7.6.4.3. Reimbursement scenario
7.6.4.4. Competitive scenario
7.6.4.5. UAE IVF market, 2021 - 2033
Chapter 8. Competitive Analysis
8.1. Company Profiles
8.1.1. Suppliers
8.1.1.1. Vitrolife
8.1.1.1.1. Overview
8.1.1.1.2. Financial Performance
8.1.1.1.3. Product Benchmarking
8.1.1.1.4. Strategic Initiatives
8.1.1.2. Emd Serono, Inc.
8.1.1.2.1. Overview
8.1.1.2.2. Financial Performance
8.1.1.2.3. Product Benchmarking
8.1.1.2.4. Strategic Initiatives
8.1.1.3. FUJIFILM Irvine Scientific
8.1.1.3.1. Overview
8.1.1.3.2. Financial Performance
8.1.1.3.3. Product Benchmarking
8.1.1.3.4. Strategic Initiatives
8.1.1.4. The Cooper Companies, Inc.
8.1.1.4.1. Overview
8.1.1.4.2. Financial Performance
8.1.1.4.3. Product Benchmarking
8.1.1.4.4. Strategic Initiatives
8.1.1.5. Thermo Fisher Scientific, Inc.
8.1.1.5.1. Overview
8.1.1.5.2. Financial Performance
8.1.1.5.3. Product Benchmarking
8.1.1.5.4. Strategic Initiatives
8.1.1.6. Bayer AG
8.1.1.6.1. Overview
8.1.1.6.2. Financial Performance
8.1.1.6.3. Product Benchmarking
8.1.1.6.4. Strategic Initiatives
8.1.1.7. Merck & Co., Inc.
8.1.1.7.1. Overview
8.1.1.7.2. Financial Performance
8.1.1.7.3. Product Benchmarking
8.1.1.7.4. Strategic Initiatives
8.1.1.8. Cook Medical LLC (Cook Group)
8.1.1.8.1. Overview
8.1.1.8.2. Financial Performance
8.1.1.8.3. Product Benchmarking
8.1.1.8.4. Strategic Initiatives
8.1.1.9. Genea Biomedx
8.1.1.9.1. Overview
8.1.1.9.2. Financial Performance
8.1.1.9.3. Product Benchmarking
8.1.1.9.4. Strategic Initiatives
8.1.1.10. Ferring Pharmaceutical B.V.
8.1.1.10.1. Overview
8.1.1.10.2. Financial Performance
8.1.1.10.3. Product Benchmarking
8.1.1.10.4. Strategic Initiatives
8.1.2. Service Providers
8.1.2.1. Nova IVF
8.1.2.1.1. Overview
8.1.2.1.2. Financial Performance
8.1.2.1.3. Service Benchmarking
8.1.2.1.4. Strategic Initiatives
8.1.2.2. Boston IVF
8.1.2.2.1. Overview
8.1.2.2.2. Financial Performance
8.1.2.2.3. Service Benchmarking
8.1.2.2.4. Strategic Initiatives
8.1.2.3. RMA Network (Reproductive Medicine Associates)
8.1.2.3.1. Overview
8.1.2.3.2. Financial Performance
8.1.2.3.3. Service Benchmarking
8.1.2.3.4. Strategic Initiatives
8.1.2.4. TFP Thames Valley Fertility
8.1.2.4.1. Overview
8.1.2.4.2. Financial Performance
8.1.2.4.3. Service Benchmarking
8.1.2.4.4. Strategic Initiatives
8.1.2.5. Fortis Healthcare
8.1.2.5.1. Overview
8.1.2.5.2. Financial Performance
8.1.2.5.3. Service Benchmarking
8.1.2.5.4. Strategic Initiatives
8.1.2.6. U.S. Fertility
8.1.2.6.1. Overview
8.1.2.6.2. Financial Performance
8.1.2.6.3. Service Benchmarking
8.1.2.6.4. Strategic Initiatives
8.2. Company Categorization
8.3. Company Market Position Analysis
8.4. Strategy Mapping
Chapter 9. Recommendations/Key Market Insights
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers